Future Med Chem. 2012 Aug;4(12):1537-9. doi: 10.4155/fmc.12.86.
Loren D Walensky is an Associate Professor of Pediatrics at Harvard Medical School, faculty member in the Department of Pediatric Hematology/Oncology at Dana-Farber Cancer Institute/Children's Hospital Boston, and Medical Director of Dana-Farber's Program in Cancer Chemical Biology. He graduated as valedictorian from Princeton University in 1990, majoring in Chemistry and receiving a Certificate in Science Policy from the Woodrow Wilson School of Public and International Affairs. He went on to receive his MD and PhD from the Johns Hopkins University School of Medicine in 1997. Dr Walensky spoke to Isaac Bruce, Commissioning Editor of Future Medicinal Chemistry, about his career in therapeutic peptides, his involvement in collaborations and funding, and the future of peptides as therapy.
洛伦·D·瓦尔恩斯基是哈佛医学院儿科学副教授，丹娜-法伯癌症研究所/波士顿儿童医院儿科血液学/肿瘤学系教员，以及丹娜-法伯癌症化学生物学项目的医疗主任。他于 1990 年以优异成绩毕业于普林斯顿大学，主修化学，并获得伍德罗·威尔逊公共和国际事务学院科学政策证书。1997 年，他进入约翰霍普金斯大学医学院获得医学博士和哲学博士学位。瓦尔恩斯基博士与未来药物化学的委托编辑艾萨克·布鲁斯（Isaac Bruce）探讨了他在治疗性肽方面的职业生涯、他在合作和资助方面的参与，以及肽作为治疗方法的未来。
